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Abstract
The mechanisms of hypertrophic scar formation are not fully understood. We previously screened the differentially
expressed genes of human hypertrophic scar tissue and identified P311 gene as upregulated. As the activities of P311 in
human fibroblast function are unknown, we examined the distribution of it and the effects of forced expression or silencing
of expression of P311. P311 expression was detected in fibroblast-like cells from the hypertrophic scar of burn injury
patients but not in peripheral blood mononuclear cells, bone marrow mesenchymal stem cells, epidermal cells or normal
skin dermal cells. Transfection of fibroblasts with P311 gene stimulated the expression of alpha-smooth muscle actin (a-
SMA), TGF-b1 and a1(I) collagen (COL1A1), and enhanced the contraction of fibroblast populated collagen lattices (FPCL). In
contrast, interference of fibroblast P311 gene expression decreased the TGF-b1 mRNA expression and reduced the
contraction of fibroblasts in FPCL. These results suggest that P311 may be involved in the pathogenesis of hypertrophic scar
via induction of a myofibroblastic phenotype and of functions such as TGF-b1 expression. P311 could be a novel target for
the control of hypertrophic scar development.
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Introduction
Hypertrophic scars are a common problem after an injury.
Clinically they present as erythematous or elevated firm plaques
that remain confined to the damaged area. However if the
formation of hypertrophic scar occurs in organs such as the lungs,
liver, kidneys, joints, and skin, it can interfere with organ function,
and ultimately result in organ failure. Even with the increasing
knowledge of wound healing, hypertrophic scars are still difficult to
prevent and to treat [1].
The formation of hypertrophic scar represents a dysregulated
response to cutaneous wound healing and is characterized by
inflammation, excessive proliferation of fibroblasts, and abnormal
deposition of extracellular matrix (ECM) proteins [2]. Despite the
fact that intrinsic differences between normal skin fibroblasts and
hypertrophic scar myofibroblasts have been demonstrated by
many studies, the underlying mechanisms promoting scar
formation remain to be elucidated.
We previously screened for genes that were differentially
expressed in hypertrophic scar and normal skin tissues of burn
patients using gene microarrays and identified 97 differentially
expressed genes. Among these P311 gene expression increased
conspicuously in hypertrophic scar tissue [3].
The P311 gene is mapped to the long arm of chromosome 5
and the protein it encodes for does not belong to any known
protein family [4]. The N-terminus of this 8 kDa protein contains
a PEST domain that is highly conserved among human, murine
and chicken proteins. This domain is a binding site of the
ubiquitin/proteasome pathway which is involved in the regulation
of expression of transcription factors, cytokines and signal factors
[5,6].
Pan et. al. reported that P311 protein and mRNA could be only
found in myofibroblasts present in human wounds. Moreover, in
their study the expression of P311 was associated with downreg-
ulation of TGF-b1 and collagen type I expression in the murine
cell lines NIH 3T3 and C3H10T1/2 [7]. However, further study
of the possible role(s) of P311 in human fibroblast function is
required as hypertrophic scar is a unique feature of humans which
is absent in other species including mice [8,9,10]. Therefore, in the
present study, we examined the effects of forced and silenced P311
gene expression on human fibroblasts functions in vitro.
Materials and Methods
Patient Inclusion Criteria
Hypertrophic scar patients were selected according to the
Vancouver Scar Scale (VSS) ranging from 10 score to 13 score
[11]. 1.Tissues were collected within 1 year of the burn injury; 2.
clinical manifestations: scar exhibited obvious hyperemia, red
appearance, and obvious hypertrophy; patient experienced
pruritus, pain, and dysesthesia of scar; local growth of the scars
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of use of immunosuppressants; 4. before surgery. All the patients
were informed of the purpose and procedure of this study and
agreed to offer their tissue specimens. The written consent was
obtained from all participants involved in this study. All the
protocols were approved by the Ethic Committee of Southwest
Hospital, Chongqing, China.
Preparation of Scar Specimens
All the hypertrophic scar specimens and the normal skin
specimens were obtained from the same patients who underwent
orthopedic surgery at the Institute of Burn Research,and the
Department of Plastic and Reconstructive Surgery of Southwest
Hospital. The specimens were either washed with PBS and
subjected to immediate cell isolation or fixed with saturated
trinitrophenol solution and storage in liquid nitrogen.
Primary cell culture
As previously described [12], fibroblasts were from normal skins
(Sk) and hypertrophic scars (Sc). Skin or hypertrophic scar tissue
was cut into 0.5 cm
3 pieces using a pair of scissors, and the
epidermis and dermis were isolated by digestion with 0.25 g/l
Dispase II (Sigma, USA). The dermal tissue was minced and
digested thoroughly with 30 volumes of 200 U/ml collagenase I
solution (Sigma, USA) (200 U collagenase I solution in 1 ml PBS)
at 37uC for 2 hours, followed by cell collection by centrifugation.
The cells were then cultured in DMEM medium containing 10%
calf serum (Hyclone, USA) at 37uC in air containing 5% CO2.
The cells were passaged 4 to 9 times and used in the following
experiments. Epidermal cells (Ep) were from normal skins. Skin
tissue was cut into 1 cm
3 pieces using scissors and digested with
2.5 g/l Dispase II (Sigma, USA) at 4uC overnight. The epidermal
tissue was collected to be digested by 2.5 g/l trypsin (Sigma, USA)
containing 0.2 g/l EDTA?Na2 (Sigma, USA) for 5 minutes. And
the epidermal cells were then cultured in K-SFM medium (Gibco,
USA) at 37uC in air containing 5% CO2. Peripheral blood
monocytes (PBM) were from the healthy peripheral blood. The
10 ml peripheral blood was diluted by 10 ml PBS, followed by
adding into 20 ml Fercoll (1.073 g/ml) (TBD, China) gently. The
cell suspension was then centrifuged at 900 g for 20 minutes at
20uC. The cells in up-interface were harvested to be diluted by
20 ml PBS. We got the peripheral blood monocytes precipitation
after centrifuge the suspension at 700 g for 10 minutes at 20uC.
Bone marrow mesenchymal stem cells (mMSC) were from healthy
bone marrow and isolated with the same protocol as that for
peripheral blood monocytes. The bone marrow mesenchymal
stem cells were identified by FACS on the cell markers of CD105
(using FITC-labeled anti-CD105 antibody, 1:50) and of CD34
(using PE-labeled anti-CD34 antibody, 1:10) (Pierce, USA). The
corresponding controls were either FITC-IgG2b (1:1000) or PE-
IgG1 (1:1000).
Preparation of replication defective adenovirus
expression vector containing human P311 gene (P311)
The P311 plasmid was a kind gift from Professor Matthieu Levi-
Srauss (Inserm U114, Chaire de Neuropharmacologie, College de
France, 11, Place Marcelin Berthelot, 75005 Paris, France).
pAdTrack-CMV plasmid and pAdEasy
TMxL Adenoviral Vector
System were purchased from Stratagene (USA). The P311 plasmid
was digested and ligated with T vector. After the recombinant was
identified by sequencing, pAdTrack-CMV/pGEM T-Easy-P311
shuttle plasmid was constructed and transfected into competent E.
coli DH5a (ATCC, USA), followed by collection of rigid clones.
Then, pAdTrack-CMV/pGEM T-Easy-P311 shuttle plasmid and
adenovirus genome-containing pAdEasy-P311 plasmid underwent
homologous recombination in E. coli BJ5183, and adenovirus
plasmid expressing the target gene was screened. The virus was
packaged and amplified in AD-293 cells, and the virus titer was
determined by means of Plaque Forming Unit(PFU).
Transduction of fibroblasts with replication defective
adenovirus expression vector
Fibroblasts were digested with 0.25 g/l trypsin, and inoculated
into 75 cm
2 culture flasks at a density of 1610
6 cells in 10 ml
DMEM medium containing 10% calf serum. Upon 80% cell
confluence, the medium was discarded, and the cells were washed
with 0.1 M PBS and antibiotic-free, serum-free DMEM medium.
Then, 1610
9 PFU/ml virus stock suspension was added to cover
the cells on the culture flask bottom. The cells were cultured for
1 hour at 37uC in air containing 5% CO2, and then the virus
suspension was removed, followed by the addition of DMEM
medium containing 10% calf serum, and cultured in an incubator.
At the indicated time points, the cultures were microscopically
examined for the expression of green fluorescent protein using an
inverted microscope (Olympus, Japan).
Preparation of the model of fibroblast populated
collagen lattice (FPCL) and measurement of fibroblast
contraction in FPCL Model
The FPCL model was used to observe the contractile ability of
fibroblasts. As described previously [13], soluble collagen was
extracted from the tails of SD rats. The cell suspension (the final
concentration: 5610
5 cells/ml), calf serum (the final concentra-
tion: 10%), 56DMEM, and collagen protein solution were mixed
at a volume ratio of 1:1:2:6 at 4uC and the pH of the mixture was
adjusted to 7.2. The fibroblast/collagen protein suspension was
added into culture dishes at a size of 35 mm in diameter, and
maintained for 10 minutes at 37uC in air containing 5% CO2 until
gel formation, followed by addition of 1 ml DMEM medium
containing 10% calf serum and further cultured at 37uC in air
containing 5% CO2. The diameter of FPCL was recorded every
other day. The FPCL contraction index is calculated as follows
[14]: CI=[12(D/D0)
2]6100% (CI: contraction index; D: diam-
eter of collagen protein gel block; D0: initial diameter of gel block
(35 mm)).
Silencing of P311 in fibroblast by shRNA
This study used three P311 shRNAs, targeting different regions
of the P311 transcript and one control shRNA contracted













GAAAAAACAGCTGTTCGA-59. And the sequences of the
control shRNA were 59-GATCCGACTTCATAAGGCGCATG-
CTTCAAGACGGCATGCGCCTTATGAAGTCTTTTTTGT-
CGACA-39 and 39-GCTGAAGTATTCCGCGTACGAAGTT-
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CGA-59. These shRNA fragments were ligated with pGenesil-1
plasmid (Genesil, China). Primary human fibroblasts containing
about 2610
4 cells were transfected with the 1 mg P311 shRNA
plasmids using 3 ml FuGene 6 non-liposome transfection reagent
(Roche, USA). Stable fibroblasts clones were selected with medium
containing G418 (400 mg/ml) for 3 weeks and the expression levels
of P311 protein were determined by Western blotting. Clones
displaying satisfactory P311 gene suppression were selected for
subsequent analysis. Scar fibroblasts expressing shRNA gene were
divided into the following groups: 1. Sc (hypertrophic scar-derived
fibroblast-like cells); 2. control (hypertrophic scar-derived fibro-
blast-like cells transfected with negative plasmid, served as control
group); 3. shRNA1 (hypertrophic scar-derived fibroblast-like cells
transfected with shRNA1 plasmid); 4. shRNA2 (hypertrophic scar-
derived fibroblast-like cells transfected with shRNA2 plasmid); 5.
shRNA3 (hypertrophic scar-derived fibroblast-like cells transfected
with shRNA3 plasmid).
Western Blotting
Cells were lysed using 1% protease inhibitor cocktail, 1%
phenymethylsulphonyl fluoride and 1% sodium orthovanadate in
RIPA lysis buffer (Santa, USA). The samples were scraped,
collected and centrifuged at 10,000 g for 30 minutes. The
supernatant was collected, and protein concentrations were
determined by Bradford assay. Equal amounts of protein were
mixed with reducing SDS sample buffer and boiled for 5 minutes
before loading onto 10% SDS-PAGE gels. Electrophoresis was
carried out under reducing conditions at 100 volts for 1.5 hours
and the separated proteins were then transferred at 100 volts over
1.5 hours to a nitrocellulose (NC) membrane (GE, USA). The
membrane was blocked with Tris-buffered saline (TBS) containing
5% non-fat powdered milk for 2 hours at room temperature and
then incubated with rabbit anti-human P311 antibody (1:1000)
(Boster, China) at 4uC overnight. The blots were subsequently
washed with TBS containing 1% Tween 20 for 4 times and then
Figure 1. The expression of P311 in different cell types. Total
RNA was isolated from cells and RT-PCR was performed to detect P311.
The groups were designed as Sc (hypertrophic scar-derived fibroblast-
like cells), Sk (skin-derived fibroblasts), Ep (epidermal cells), PBM
(peripheral blood monocytes) and mMSC (bone marrow mesenchymal
stem cells). Representative result is from 1 of 10 experiments.
doi:10.1371/journal.pone.0009995.g001
Figure 2. The effect of P311 on fibroblast functions after P311 gene upregulation. Total RNA was isolated from fibroblasts and RT-PCR was
performed to compare a-SMA, TGF-b1 and a1(I) collagen gene(COL1A1) mRNA levels in different treated groups. (A) Hypertrophic scar-derived
fibroblast-like cells were transduced with adenovirus P311 and cultured as described under materials and methods. The groups were designed as Sc
(hypertrophic scar-derived fibroblast-like cells), Sc+Ad (hypertrophic scar-derived fibroblast-like cells +adenovirus void vector) and Sc+P311
(hypertrophic scar-derived fibroblast-like cells +P311). (B) Normal skin-derived fibroblasts were transduced with adenovirus P311. The groups were Sk
(normal skin-derived fibroblasts), Sk+Ad (normal skin-derived fibroblasts+adenovirus void vector) and Sk+P311 (normal skin-derived
fibroblasts+P311), * means P,0.01 between the two groups. (C, D) Transduction of P311 into normal skin-derived fibroblasts increased the S-
Phase cell fraction as determined by FACS. (C) Control group (6200). (D) P311 transduced group (6200). A representative analysis of 3 experiments is
shown.
doi:10.1371/journal.pone.0009995.g002
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(1:2000) (Boster, China) for 2 hours at room temperature. Proteins
were washed with TBS containing 1% Tween 20 for 4 times again,
and visualized using enhanced chemiluminescence (Pierce, USA)
according to the manufacturer’s instructions.
RT-PCR
P311 mRNA expression was detected in skin- and hypertrophic
scar-derived fibroblasts by RT-PCR, and the expression of a-
SMA, TGF-b1, a1(I) collagen gene (COL1A1) mRNAs were
detected in fibroblasts before and after P311 gene transduction.
The primers for the genes were designed according to the
sequence registered in Genbank, and synthesized by Shanghai
Bioaisa Biotech Co. Ltd. Total RNA was extracted from cultured
cells with TRIzol reagent (Gibco, USA). RT-PCR was performed
as described previously. The RNA was made at 42uC for 15
minutes using AMV reverse transcriptase (Promega, USA) and
oligo(dT) as a primer. The optimal reaction conditions were
determined for each experimental group and primers. The
primers for P311 were 59-GCACATATGGTTTATTACCCAG-
39 and 59-CAGGATCCTTAAAAAAAGTGGAGG-39. The
primers for a-SMA were 59-GGTGATGGTGGGAATGG-39
and 59-TGGCTGGAACAGGGTCT-39. The primers for TGF-
b1 were 59-CTGTGGCTACTGGTGCTGAC-39 and 59-CAT-
AGATTTCGTTGTGGGTTTC-39. The primers for a1(I) colla-
gen gene(COL1A1) were 59-TCTTTGAATCCTAGCCCATC-
39 and 59-GGAGCACCTTTACAAGCAGT-39. The primers for
glyceraldehyde phosphodehydrogenase(GAPDH) were. 59-CG-
TCTTCACCACCATGGAGA-39 and 59-CGGCCATCGCCA-
CAGTTT-39. Reaction conditions were 5minutes at 94uC and 35
cycles of 94uC for 30 seconds, 55uC for 30 seconds, and 72uC for
40 seconds. GAPDH was used as an internal control. PCR
products were separated by electrophoresis on 1% agarose gels,
stained with ethidium bromide, and photographed against
ultraviolet light. Expression levels of target genes were normalized
by concurrently measured GAPDH mRNA levels. The mRNA
relative content can be showed by the ratio of its PCR and
GADPH absorbency.
Analysis of cell cycle by FACS
Cells were detached in 0.25 g/l trypsin and washed twice in ice-
cold PBS. Followed by fixation in 70% ethanol in 4uC overnight,
cells were washed 2 additional times in PBS, and then stained for
30 minutes at 37uCi n5 0mg/ml propidium iodide (Sigma, USA)
solution containing 200 mg/ml RNase A and 0.1% Triton-X-100.
Samples were stored at 4uC until analysis by FACS (BD, USA).
Statistical analysis
Measurement data were presented as means 6 standard
deviation (SD) and analyzed by one-way ANOVA test in
conjunction with LSD test. The differences between multiple
specimens were analyzed when necessary. P value less than 0.05
was considered as the statistical significance.
Results
The distribution of P311
The expression pattern of P311 mRNA was examined in several
human cell types by means of RT-PCR. P311 was readily
detectable in dermal fibroblast-like cells derived from hypertrophic
scar tissue. However, it was not detected in the normal skin-
derived dermal fibroblasts, epidermal cells, peripheral blood
mononuclear cells or bone marrow mesenchymal stem cells (Fig. 1).
The effect of P311 over expression on fibroblast
functions
The effects of transduction of the human P311 gene or its empty
control virus into hypertrophic scar-derived or normal dermal
fibroblasts were examined. We observed that normal skin-derived
fibroblasts do not express a-SMA or TGF-b1 (Fig. 2B). Following
transduction with a P311 expression vector, a-SMA, TGF-b1, and
COL1A1 mRNAs were all increased (Fig. 2B). Moreover, the
proportion of cells in S phase was increased from 0.3% to 6.0%
following P311 expression (Fig. 2C and 2D).
In contrast hypertrophic scar-derived dermal fibroblast-like cells
constitutively express a-SMA, TGF-b1, and COL1A1 (Fig. 2A1
and 2A2). However, the upregulation of P311 did increased the
expression of a-SMA, TGF-b1, and COL1A1 mRNA.
The ability to induce collagen contraction is a characteristic
feature of myofibroblasts [15]. A comparison of the contractile
activities of normal skin-derived fibroblasts with those derived
from hypertrophic scar indicated that the normal cells expressed
lower activity (Fig. 3). Transduction of P311 into normal skin-
derived fibroblasts markedly enhanced their ability to contract
collagen gels (Fig. 3). Similarly transduction of P311 into
hypertrophic scar derived fibroblast-like cells significantly en-
hanced their ability to contract the gels (Fig. 3).
The suppression of P311 expression inhibited scar-
derived fibroblast-like cells functions
The above observations suggested that P311 expression induces
a number of the phenotypic properties observed in hypertrophic
scar derived fibroblast-like cells. Furthermore as P311 expression
was elevated in scar tissues, we tested the effects of inhibition of
Figure 3. The contraction of collagen by fibroblasts. Normal skin-
and hypertrophic scar-derived fibroblasts were transduced with
recombinant adenovirus P311 as described in Materials and Methods
Section. The groups were designed as Sk (normal skin-derived
fibroblasts), Sk+Ad (normal skin-derived fibroblasts+adenovirus void
vector), Sk+P311 (normal skin-derived fibroblasts+P311), Sc (hypertro-
phic scar-derived fibroblast-like cells), Sc+Ad (hypertrophic scar-derived
fibroblast-like cells +adenovirus void vector and Sc+P311 (hypertrophic
scar-derived fibroblast-like cells +P31). (A) Normal skin- and hypertro-
phic scar-derived fibroblasts were transduced with adenovirus P311,
and cultured in a collagen lattice for 13 days. (B) P311 enhanced the
contractile ability of fibroblasts obviously. The FPCL model was cultured
for 1, 2, 3 and 4 weeks. The contraction index was calculated as previous
described. * means p,0.01 as compared with the control group
without P311. m means p,0.01 between hypertrophic scar-derived
fibroblast-like cells and normal skin-derived fibroblasts. A representative
analysis of 3 experiments is shown.
doi:10.1371/journal.pone.0009995.g003
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cells.
Transfection of scar-derived fibroblast-like cells with a shRNA
targeting P311 (shRNA1) significantly lowered the expression
levels of P311 protein as detected by western blot (Fig. 4A). These
cells displayed reduced levels of TGF-b1 expression (Fig. 4B).
Significantly, there was a partial loss of the contractile ability of
fibroblast-like cells in the FPCL model following the suppression of
P311 (Fig. 4C).
Discussion
The formation of hypertrophic scar is an abnormal wound
healing response after trauma. Histologically and clinically,
hypertrophic scar is characterized by excessive fibroblast
hypertrophy, accumulation of extracellular matrix and con-
tracture [16,17,18,19]. At the molecular level, TGF-b is
considered to be the critical regulator involved in the
formation of hypertrophic scar [20,21]. However, there are
currently no approaches based on this paradigm which
completely prevent scar formation or treat existing scar
[1,20,22]. This leads us to search for additional potentially
unknown factors involved in hypertrophic scar formation,
which might aid our understanding of hypertrophic scar
formation. Such information might also suggest novel strate-
gies for controlling scar formation.
Our previous microarray analysis revealed that P311 was highly
upregulated in hypertrophic scar tissue [3]. Meanwhile, Pan et. al.
showed that P311 was found in human wounds during healing and
disappeared after wound healed [7]. Importantly, Pan also
demonstrated that transfection of P311 into murine cell line
NIH 3T3 or C3H10 T1/2 could significantly stimulate the
differentiation of fibroblasts to myofibroblasts via a TGF-b1
independent signaling pathway. Significantly, these results were
not obtained with human fibroblasts. The combination of our
previous work [3] and that of Pan et. al. prompted us to explore
the possible roles of P311 in human fibroblast function.
An examination of P311 mRNA expression in a number of
human cell types revealed that P311 mRNA expression was only
detected in hypertrophic scar-derived fibroblast-like cells. These
results are consistent with the finding of immunohistochemical
studies of Pan et. al. [7]. These observations suggest that P311
expression may be involved in normal and hypertrophic scar
formation.
Our results show that the expression of P311 can induce the
expression of a–SMA (Fig. 2B) in normal skin-derived fibroblasts.
As a-SMA is a putative cell marker of myofibroblasts [23], this
result suggests that P311 may induce the myofibroblast phenotype.
Figure 4. The expression of TGF-b1 by fibroblasts after P311 shRNA plasmid transfection. (A) Total protein was extracted from
hypertrophic scar-derived fibroblast-like cells transfected with P311 shRNA plasmids. Western blotting demonstrated that shRNA1 plasmid was the
most effective plasmid for silencing P311 protein expression in fibroblasts. * means P,0.01 between the two groups. (A1) The expression of P311
protein is demonstrated by Western blotting. (A2) The lowest expression of P311 protein was found in shRNA1 group. (B) Hypertrophic scar-derived
fibroblast-like cells transfected with P311 shRNA plasmids showed lower expression of TGF-b1 than control. * means P,0.01 between the two
groups. (B1) Total RNA was isolated from hypertrophic scar-derived fibroblast-like cells and RT-PCR was performed to determine TGF-b1 mRNA level.
(B2) Histogram showed the downregulation of TGF-b1 mRNA level in P311 silenced hypertrophic scar-derived fibroblast-like cells. (C) Hypertrophic
scar-derived fibroblast-like cells were transduced with shRNA of P311. The groups were Sc+control (hypertrophic scar-derived fibroblast-like cells +
negtive vector (control)) and Sc+ shRNA1 (hypertrophic scar-derived fibroblast-like cells + P311 shRNA1). (C1) Hypertrophic scar-derived fibroblast-like
cells were transfected with P311 shRNA plasmids and cultured in a collagen lattice for 2 weeks. (C2) Absence of P311 inhibited the contractile ability
of hypertrophic scar-derived fibroblasts. * means p,0.01 considered as statistical significance as compared with the control group with negative
shRNA plasmids (control). A representative analysis of 3 experiments is shown.
doi:10.1371/journal.pone.0009995.g004
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fibroblasts [7]. However our current work also indicated that the
forced expression of P311 was associated with increased levels of
TGF-b1 and COL1A1 mRNA in both normal skin-derived and
hypertrophic scar-derived fibroblast-like cells (Fig. 2A2 and 2B)
relative to the corresponding control transductants. Conversely
inhibition of P311 gene expression resulted in a reduction in the
expression of TGF-b1. In addition, after P311 gene transduction,
more fibroblasts entered into the S phase of cell cycle (Fig. 2D),
which implies that P311 can stimulate the proliferation of
fibroblasts. Our results indicate that P311 promotes the produc-
tion of TGF-b and COL1A1 in human fibroblasts, and stimulates
their proliferation and differentiation to myofibroblasts.
We tested the role of P311 in the contraction of fibroblasts in
FPCL model in vitro, as myofibroblasts are believed to be
responsible for the contraction of hypertrophic scar [24] and a–
SMA positive myofibroblasts can cause the contraction of FPCL in
vitro [13,15]. Expression of P311 gene was associated with an
enhanced level of contraction in normal and hypertrophic scar-
derived fibroblasts (Fig. 3). On the other hand, suppression of
P311 expression in hypertrophic scar-derived fibroblasts-like cells
inhibited the capacity of these cells to mediated collagen
contraction (Fig. 4C). These data indicate that P311 gene might
be also involved in the contraction of hypertrophic scar.
TGF-b1 is considered as the key paracrine/autocrine growth
factor in induction and maintenance of the hypertrophic scar. In
addition the signaling pathway of TGF-b1 initiates a mechanistic
cascade involving activation of fibroblast differentiation which
promotes the synthesis of a–SMA and the extracellular matrix,
mainly collagen I, with enhanced the contractile ability [1].
Therefore, we hypothesize that P311 induces fibroblast differen-
tiation via enhancing the TGF-b1 signaling pathway in human
hypertrophic scar.
Our results do not seem to be consistent with those of Pan et al
which suggested that P311 induced TGF-b1-independent myofi-
broblast transformation. We do observe myofibroblast transfor-
mation but this occurs in the presence of up regulation of TGF-b1
and collagen. The former results were based on data obtained with
murine fibroblasts. Hypertrophic scars appear to be unique to
humans as no animals are known to form these lesions [8,9,10].
Furthermore, animal models including athymic mice, rats,
hamster cheek pouch, guinea pigs and rabbit ear models present
significant differences when compared with human hypertrophic
scars suggesting that these may have different pathogenic
mechanisms than human hypertrophic scar [25]. In our study,
we employed human fibroblasts from normal skin and hypertro-
phic scar as the target cells which is consistent with the
pathogenesis of human hypertrophic scar. The results of our
study suggest that P311 may have different regulatory functions in
fibroblasts of human origin compared with in murine fibroblasts.
In summary, our work for the first time shows the function of
P311 gene in human fibroblasts, i.e., P311 gene can stimulate
human fibroblast proliferation, induce myofibroblast phenotype,
promote the expression of TGF-b1 and COL1A1, and enhance
the contraction of human fibroblasts in FCPL. These data strongly
indicate that P311 may be involved in the hypertrophic scar
pathogenesis and contraction via enhancing the expression of
TGF-b1. Further studies of P311 function may provide new
insights into the molecular events of hypertrophic scar formation
and possibly provide new approaches for the control of
hypertrophic scar formation.
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